Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 806-510-7 | CAS number: 1393571-43-1
The toxicokinetic assessment is based on the test results and a theoretical evaluation of uptake, distribution, metabolism and excretion
A toxicokinetic assessment for Fatty acids, tall-oil, reaction products with fatty acids C16-C18 and C18-unsatd, branched and linear, diethylenetriamine and citric acid has been made based on the physical and chemical properties of the substance and the available toxicity studieson the substance and the analogues, Fatty acids, tall-oil, reaction products with diethylenetriamine, maleic anhydride, tetraethylenepentamine and triethylenetetramine andfatty acids, tall-oil, reaction products with diethylenetriamine and maleic anhydride(see table under physicochemical properties). The properties of the analogues are considered sufficiently similar to those of the test substance to allow read-across (see chapter 13, document on read-across).A substance can enter the body via the lungs, the gastrointestinal tract, and the skin. To determine the absorption rate, the different routes need to be assessed individually.
The size of the molecule, log Kow and water solubility are important factors in uptake and distribution of chemicals. Based on the data generated for the substance, it can be concluded that the log Kow is high (ca. 11) and the water solubility is low (ca. 0.57 mg/L mg/L). Most of the components in this UVCB substance are a-polar, due to the large a-polar tails of the incorporated fatty acids. Molecular weights range from 759 to 850 Da.
In general, a compound needs to be dissolved before it can be taken up from the gastro-intestinal tract after oral administration.
(1) The substance has low water solubility, therefore it is expected to dissolve to a small extent into the gastrointestinal fluids. Uptake by passive diffusion is thus limited.
(2) Based on the molecular weight range, absorption is expected to be low.
(3) The substance has a high log Kow, which makes the compound very hydrophobic. This characteristic will enable micellular solubilisation by bile salts in the gastro-intestinal tract which allows crossing of lipid biomembranes.
In the available 90-day study with the analogue,fatty acids, tall-oil, reaction products with diethylenetriamine and maleic anhydride (Charles River 2016), no adverse effects were reported at any of the tested doses (NOAEL 1000 mg/kg bw). This can be either indicative for low systemic availability or for low toxicity. In a developmental toxicity with the same analogue no effects were found related to maternal or developmental toxicity (NOAEL 1000 mg/kg bw, Charles River 2016).
In the repeated dose-reproduction study available on the analogue Fatty acids, tall-oil, reaction products with diethylenetriamine, maleic anhydride, tetraethylenepentamine and triethylenetetramine (BSL 2010c), no systemic effects were found after oral administration.The multifocal bronchopneumonia in the lungs reported in the repeated dose study in rats were attributed to reuptake of part of the stomach contents and as such do not provide evidence for absorption via the oral route.
Based on this finding and the physicochemical properties as discussed above, limited or no absorption of the test substance is anticipated. The oral absorption is therefore set at 10%.
Table 1. Main physicochemical characteristics
Fatty acids, tall-oil, reaction products with fatty acids C16-C18 and C18-unsatd, branched and linear, diethylenetriamine and citric acid
Fatty acids, tall-oil, reaction products with diethylenetriamine, maleic anhydride, tetraethylenepentamine and triethylenetetramine
Fatty acids, tall-oil, reaction products with diethylenetriamine and maleic anhydride
State of the substance at 20°C and 101,3 kPa
extremely viscous liquid
Melting / freezing point
50 °C (pour point)
1.9E-03 Pa at 20.0 °C
Waiver (melting point > 300 °C)
2.173 mg/L ( undissolved substance present)
Waiver (not measurable for UVCB, calculation with Petrorisk)
>6.5 (test) ca. 11 QSAR
When the substance comes in contact with the skin, the first layer of the skin, the stratum corneum, forms a barrier for hydrophilic compounds. The substance has a log Pow > 6, suggesting that the substance can be taken up in the stratum corneum. Due to its low water solubility (0.57 mg/L), the transfer between the stratum corneum and the epidermis will be limited.
In vitroskin irritation and corrosion studies show that the substance is not irritant and/or corrosive.The available acute dermal toxicity test with the analogue (BSL 2010a) does not indicate any systemic effects, but showed some very slight irritation. The substance is a skin sensitizer and is therefore expected to have some potential for dermal absorption.
Theeffects in the lungs in the repeated dose study with the analogue are related to the oral exposure route. The other available studies onfatty acids, tall-oil, reaction products with diethylenetriamine and maleic anhydridedo not show any systemic effects and can be used for route-route extrapolation.
According to the criteria given in the REACH Guidance, 10% dermal absorption will be considered in cases where the MW >500 and log Pow <-1 or >4. The weight of evidence of the following factors indicates that the substance can be assumed to have a dermal absorption of 10%:
1) the molecular weight (759-850) fulfils the criterion
2) the log P is considerably outside the stated range (ca. 11) and
3) skin irritation testing did not report any corrosive effects which would enhance absorption significantly.
The low vapour pressure (1.9E-03Pa) indicates that the substance is not expected to evaporate and become available via inhalation. Moreover, aerosol formation is not expected from the current uses. Therefore exposure of the respiratory tract is not likely. If, however, the test substance would reach the tracheobronchial region, it is not likely to dissolve within the mucus lining the respiratory tract due to its low water solubility. But based on its high log Kow, micellular solubilisation may occur which could enable some uptake of the substance by crossing of biomembranes. This is confirmed by the results of the repeated dose-reproduction study on the analogue (BSL 2010c), where effects in the lungs become apparent when the lungs are exposed to the stomach content.Based on the above data, for risk assessment purposes the inhalation absorption of the substance is set at 10%.
Both the oral and the inhalation route are considered not relevant as exposure routes and are therefore not further considered.
Bioavailability and metabolism
Once absorbed, wide distribution of the test substance throughout the body is not expected based on its low water solubility. This is in line with the findings in the 90-day study and the developmental toxicity study withfatty acids, tall-oil, reaction products with diethylenetriamine and maleic anhydride(Charles River 2016). Fatty acids, tall-oil, reaction products with fatty acids C16-C18 and C18-unsatd, branched and linear, diethylenetriamine and citric acid has a molecular weight of759 to 850 Da. In general, molecules of this size do not pass readily through cell membranes thus limiting wide distribution. Based on its size and its low water solubility, distribution is expected to be limited. Based on its high partition coefficient (ca. 11), it might initially be assumed that some test substance will distribute into cells and accumulate in adipose tissue. However, for highly hydrophobic substances, experimental data demonstrate that bioaccumulation factor (BCF) values tend to decrease with increasing log Kow above 6. For the substance therefore no bioaccumulation is expected.
Any absorbedcomponents of the test substance are expected to be metabolized to some extent. For the fatty acid tails ß-oxidation is likely to be the major fate in mammals. Fatty acids are oxidized in mitochondria by a sequence of reactions in which the fatty acyl chain is shortened two carbon atoms at a time.The test substance contains citric acid, which is an endogenous compound in mammalian and non-mammalian species.
Excretion of the test substance will be via the faeces either via the bile (high molecular weight) or directly without becoming systemically available.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again